The notices it replaced
- Reissues: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 2 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 3 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-14-072.
Who won it before
142 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $40,857,386 in first-year total cost, median $224,904.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OTC-T (10)]14
- Special Emphasis Panel[ZRG1 ETTN-M (11)]13
- Special Emphasis Panel[ZRG1 SBIB-T (10)]9
- Special Emphasis Panel[ZRG1 CVRS-C (10)]7
- Special Emphasis Panel[ZRG1 CVRS-M (11)]6
Most frequent institutions
- BARRON ASSOCIATES, INC.2
- CUREVEDA, LLC2
- EPIGEN BIOSCIENCES, INC.2
- EXSCIEN CORPORATION2
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2016 | Development of Alkontrol herbal for Treating Alcohol Abuse1R42AA022577-01A1 | LI, HAIXIALUKAS, SCOTT E | NATURAL PHARMACIA INTERNATIONAL, INC., MA | $154,747 | ZRG1 |
| 2015 | Evidenced-based Firefighter Worksite Health and Safety Intervention2R42TR000357-02 | ELLIOT, DIANE LOUISEGOLDBERG, LINN | ODYSSEY SCIENCE INNOVATIONS, LLC, OR | $714,294 | ZRG1 |
| 2015 | A Force-controlled Probe Based Platform for Single-Cell Biomolecular Delivery2R44GM101833-02 | YANG, RUIGUO | INFINITESIMAL, LLC, IL | $499,999 | ZRG1 |
| 2015 | AFM based nanoscale IR Spectroscopy (AFM-IR) as a characterization platform for P2R42GM100657-02 | TAYLOR, LYNNE S | ANASYS INSTRUMENTS CORPORATION, CA | $495,193 | ZRG1 |
| 2014 | Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease2R42AI100418-03A1 | MACKEY, MATTHEW F.NOELLE, RANDOLPH J. | IMMUNEXT, INC., NH | $995,160 | ZRG1 |
| 2014 | ECG Device for LQTS Screening in Newborns, Phase II2R42HL112435-03 | CHANG, RUEY-KANG R | QT MEDICAL, INC., CA | $983,622 | ZRG1 |
| 2014 | Brain penetrant Hsp90 inhibitors for Alzheimer's disease2R42AG042205-02 | GLICKSMAN, MARCIE AHODGETTS, KEVINPERRELLA, YUKARI | YUMA THERAPEUTICS CORPORATION, MA | $958,570 | ZRG1 |
| 2014 | Emergency Operations Plans for Individuals with Disabilities2R42HD069070-02 | HAMAD, CHARLES | PRAXIS, INC., MA | $737,154 | ZRG1 |
| 2014 | Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety2R42MH094019-03 | BEIDEL, DEBORAH CMCDANIEL, DAWN | VIRTUALLY BETTER, INC., GA | $693,414 | ZRG1 |
| 2014 | A Rapid Assay for RNA Targeted Drugs2R42GM097917-02A1 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $684,746 | ZRG1 |
| 2014 | A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology2R42CA156901-02A1 | VON WINDHEIM, JESKO | ZENALUX BIOMEDICAL, INC., NC | $679,384 | ZRG1 |
| 2014 | Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p2R42AI098192-02A1 | POLLARD, ANGELA MARIE | AGILE SCIENCES, INC., NC | $672,768 | ZRG1 |
| 2014 | Measurement of Beta Cell Death in Diabetes2R42DK095639-02 | HEROLD, KEVAN C | L2 DIAGNOSTICS, LLC, CT | $661,513 | ZRG1 |
| 2014 | SoundTrak: A Data Acquisition and Analysis System for OSDB2R42HD063272-02 | CLARK, BRIAN RPARKER, B EUGENE | BARRON ASSOCIATES, INC., VA | $655,599 | ZRG1 |
| 2014 | A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors2R42CA156930-02 | BACHOVCHIN, WILLIAM WJONES, BARRY | ARISAPH PHARMACEUTICALS, INC., MA | $534,844 | ZRG1 |
| 2014 | A Short Instrumented Test of Mobility for Neurological Disorders2R42HD071760-03 | EL-GOHARY, MAHMOUDHORAK, FAY BAHLING | APDM, INC., OR | $513,213 | ZRG1 |
| 2014 | Micro-targeted Computerized Alcohol Misuse Intervention System for Health Care2R42AA020451-02 | CALDWELL, DIANA HOWARD | RESEARCH CIRCLE ASSOCIATES, LLC, MD | $510,889 | ZRG1 |
| 2014 | An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re2R42CA183708-03A1 | PARSONS, CHRISTOPHER H | APOGEE BIOTECHNOLOGY CORPORATION, PA | $509,024 | ZRG1 |
| 2014 | Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer2R42CA156933-02A1 | KOPECEK, JINDRICH H. | THERATARGET, UT | $502,857 | ZRG1 |
| 2014 | Coils for Human Whole Body Imaging at 7T2R42EB013543-02 | VAUGHAN, JOHN T | LIFE SERVICES, LLC, MN | $502,487 | ZRG1 |
| 2014 | Slip Flow Chromatography2R42GM106580-02 | WIRTH, MARY J. | BIOVIDRIA, INC., AZ | $500,996 | ZRG1 |
| 2014 | Development of a clinical hemoglobin modulator2R42HL110727-02 | PERRINE, SUSAN PARK | PHOENICIA BIOSCIENCES, INC., MA | $499,996 | ZRG1 |
| 2014 | Automated Image-based Biomarker Computation Tools for Diabetic Retinopathy2R42TR000377-02 | SOLANKI, KAUSHAL | EYENUK, INC., CA | $490,830 | ZRG1 |
| 2014 | Experience Success: Virtual Reality Skills Training to Enhance e-Weight Loss2R42DK103537-02 | THOMAS, JOHN GRAHAMTUERK, PETER | VIRTUALLY BETTER, INC., GA | $488,788 | ZRG1 |
| 2014 | Computer-based Prescription Opioid Abuse Prevention for Adolescents2R42DA023731-02 · under PA-10-051 | MARSCH, LISA A. | HEALTHSIM, INC., NY | $450,459 | ZRG1 |
| 2014 | Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II2R42DK091141-02 | HOOVER, ADAM | BITE TECHNOLOGIES, LLC, SC | $445,349 | ZRG1 |
| 2014 | Chitosan Endoluminal Hemostatic Dressing2R42DK078400-02A1 | MCCARTHY, SIMON JOHNXIE, HUA | HEMCON, INC., OR | $424,827 | UGPP |
| 2014 | Therapeutics for inflammatory bowel disease from the microbiome1R41DK103361-01 | MAZMANIAN, SARKIS K | SYMBIOTIX BIOTHERAPIES, INC., MA | $396,794 | ZRG1 |
| 2014 | Infant Assessment of Early Communication Risk Factors : The ISCBS (formerly ECBS)2R42DC012009-02 · under PA-13-089 | CRESS, CYNTHIA J | PAUL H. BROOKES PUBLISHING COMPANY, INC., MD | $389,759 | ZRG1 |
| 2014 | Advanced Bicycle Helmet Technology for Prevention of Traumatic Brain Injury2R42NS074734-02 · under PA-13-089 | BOTTLANG, MICHAEL | APEX BIOMEDICAL COMPANY, LLC, OR | $385,311 | ZRG1 |
| 2014 | Developing Intravesical Liposomes for Interstitial Cystitis2R42DK085733-04 | KAUFMAN, JONATHAN H | LIPELLA PHARMACEUTICALS, INC., PA | $368,266 | UGPP |
| 2014 | Novel commensal polysaccharide treats multiple sclerosis through Treg modulation1R41AI110170-01 · under PA-13-089 | KASPER, LLOYD H | SYMBIOTIX BIOTHERAPIES, INC., MA | $322,928 | ZRG1 |
| 2014 | C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS1R41HL122022-01A1 | BUCK, MARTINACHOJKIER, MARIO | XFIBRA, INC., CA | $311,803 | ZRG1 |
| 2014 | Multi-Blot Western Device1R41GM106494-01A1 · under PA-13-089 | CHIEN, STANLEY YUNG-PING | YC BIOELECTRIC, LLC, IN | $307,787 | ZRG1 |
| 2014 | Rabbit InMAD Discovery of Novel Biomarkers for POC Tuberculosis Diagnostic Assay1R41AI104377-01A1 · under PA-12-089 | BAUMAN, SEAN | IMMUNO-MYCOLOGICS, INC., OK | $299,640 | ZRG1 |
| 2014 | Discovery of novel small molecule analgesics1R41NS086244-01A1 | ISSEROFF, ROSLYN RIVKAHRAVULA, SATHEESH BYAKSH, TONY L. | EPIGEN BIOSCIENCES, INC., CA | $244,999 | ZRG1 |
| 2014 | Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV81R42HL122038-01A1 | HAMMOND, H. KIRK | RENOVA THERAPEUTICS, INC., CA | $240,750 | ZRG1 |
| 2014 | Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury1R42NS086274-01 · under PA-13-089 | KEANE, ROBERT W | INFLAMACORE, LLC, FL | $240,656 | ZRG1 |
| 2014 | Novel Small Molecule Therapeutics for Pancreatic Cancer1R41CA176931-01A1 · under PA-13-089 | CASHMAN, JOHN RCHEN, SIGENGOKOLOTOWICZ, KARL J | CHEMREGEN INC, CA | $240,555 | ZRG1 |
| 2014 | Corneal Endothelial Stem Cells for Treatment of Corneal Endothelial Dystrophies1R41EY024217-01A1 | DAS, HIRANMOY | RASHMIVU, LLC, OH | $226,007 | ZRG1 |
| 2014 | Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives1R42NS087700-01 | LEEDS, JANET | SOLANO PHARMACEUTICALS, INC., CA | $225,959 | ZRG1 |
| 2014 | An innovative in situ cell reprogramming technology for cancer treatment1R41CA183103-01 · under PA-13-089 | JIANG, FENGLI, QIANQIANWANG, JIANJUN | QURGEN, INC., MI | $225,000 | ZRG1 |
| 2014 | Development of VPL Vaccine for RSV1R41AI109926-01 · under PA-13-089 | BLANCO, JORGE C | SIGMOVIR BIOSYSTEMS, INC., MD | $225,000 | ZRG1 |
| 2014 | Orally available transition state inhibitors for triple negative breast cancer1R41CA183201-01 · under PA-13-089 | ISAACMAN, STEVENSCHRAMM, VERN L. | NANOMETICS, LLC, CA | $225,000 | ZRG1 |
| 2014 | DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis1R41CA192567-01 · under PA-13-089 | WALISH, JOSEPH | DYNUPOL, INC., MA | $225,000 | ZRG1 |
| 2014 | Assessing muscle health in older adults with electrical impedance myography1R41AG047021-01 · under PA-13-089 | BEAN, JONATHAN FBOHORQUEZ, JOSE LUIS | MYOLEX, INC., MA | $225,000 | ZRG1 |
| 2014 | Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp1R41CA183266-01 · under PA-13-089 | HAZLEHURST, LORI AMCLAUGHLIN, MARK L | MODULATION THERAPEUTICS, INC., WV | $225,000 | ZRG1 |
| 2014 | Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema1R41CA183335-01 · under PA-13-089 | HSU, SHEAU-YU TEDDY | ADEPTHERA, LLC, CA | $225,000 | ZRG1 |
| 2014 | Screening for Novel CBS Inhibitors for Cancer Therapy1R41CA186288-01 | HELLMICH, MARK R | CBS THERAPEUTICS, INC., TX | $225,000 | ZRG1 |
| 2014 | Mucins in the Diagnosis and Prognosis of Pancreatic Diseases1R41CA177288-01A1 | SASSON, AARON R | SANGUINE DIAGNOSTICS AND THERAPEUTICS, NE | $225,000 | ZRG1 |
| 2014 | Development of Novel Small Molecule Therapies for Skeletal Muscle Atrophy1R41AG047684-01 | ADAMS, CHRISTOPHER MEBERT, SCOTT MATTHEWTALLEY, JOHN JEFFREY | EMMYON, INC., MN | $225,000 | ZRG1 |
| 2014 | AutoRegister: A system for enhancing the accuracy of tumor change detection1R41CA183150-01A1 | FISCHL, BRUCESCHMANSKY, NICHOLAS JOHN | CORTICOMETRICS, LLC, MA | $225,000 | ZRG1 |
| 2014 | Novel Therapeutic Opportunity in Stroke1R41NS087684-01 | BEATON, GRAHAMUTESHEV, VICTOR V | EPIGEN BIOSCIENCES, INC., CA | $225,000 | ZRG1 |
| 2014 | Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT1R41HL123126-01 | SACHAIS, BRUCE S | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $225,000 | ZRG1 |
| 2014 | Enable Early and Sensitive In Vivo Detection of Liver Metastasis by Protein-based1R41CA183376-01A1 | YANG, JENNY J. | INLIGHTA BIOSCIENCES, LLC, GA | $225,000 | ZRG1 |
| 2014 | Robotic whole organism HTS platform for drug discovery and development1R41TR000945-01A1 | MUMM, JEFFREY | LUMINOMICS, INC., MD | $225,000 | ZRG1 |
| 2014 | High-Purity Peptide Libraries without Chromatographic Separation1R41ES025294-01 | KUMAR, KRISHNA | VERAQUEL TECHNOLOGIES, INC., MA | $225,000 | ZRG1 |
| 2014 | New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto1R41AI112302-01 | PITNER, JAMES BRUCE | NIRVANA SCIENCES, INC., NC | $225,000 | ZRG1 |
| 2014 | Rapid Screening Assay for Novel Epigenetic Drugs1R41ES025597-01A1 | ROUNTREE, MICHAEL | NZUMBE EPIGENETICS, OR | $225,000 | ZRG1 |
| 2014 | RAP as a therapeutic for regeneration of the optic nerve after insult1R41EY024803-01 | BRIGHT, ANDREW TAYLORGOLDBERG, JEFFREY L | NOVORON BIOSCIENCE, INC., CA | $225,000 | ZRG1 |
| 2014 | Exosomal drug formulations1R41CA189517-01 | GUPTA, RAMESH C | 3P BIOTECHNOLOGIES, INC., KY | $225,000 | ZRG1 |
| 2014 | F10: a novel therapeutic to treat refractory or relapsed AML1R41CA189480-01 | RAMABHADRAN, RAM | SOUTHEAST TECHINVENTURES, INC., NC | $225,000 | ZRG1 |
| 2014 | Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification1R41DK103548-01 | KUMAR, KRISHNA | VERAQUEL TECHNOLOGIES, INC., MA | $225,000 | ZRG1 |
| 2014 | Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS1R41GM112516-01 | SMITHGALL, THOMAS E. | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $225,000 | ADDT |
| 2014 | ChemoFilter: A Novel Catheter Device to Enable High-Dose Chemotherapy Treatment1R41CA183327-01 · under PA-13-089 | PATEL, ANAND S | CHEMOFILTER, INC., CA | $224,999 | ZRG1 |
| 2014 | A New MicroRNA-1291 Replacement Therapy for Pancreatic Cancer Disease1R41AA024029-01 · under PA-12-089 | BADER, ANDREAS GYU, AIMING | MIRNA THERAPEUTICS, INC., TX | $224,996 | ZRG1 |
| 2014 | Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage1R41NS086267-01A1 | WILSON, GLENN | EXSCIEN CORPORATION, AL | $224,989 | ZRG1 |
| 2014 | RAP as a therapeutic compound for neuronal regeneration after spinal cord injury1R41NS086197-01A1 | LEE, JAE KSTILES, TRAVIS LEE | NOVORON BIOSCIENCE, INC., CA | $224,952 | ZRG1 |
| 2014 | Smartphone Help for DWI Offenders and Their Families: A B-SMART App1R41AA022850-01A1 | WOODALL, W GILL | KLEIN BUENDEL, INC., CO | $224,943 | ZRG1 |
| 2014 | Intra-procedure Deformable Ultrasound-MRI Fusion for Prostate Biopsies1R41CA186414-01 | PAPADEMETRIS, XENOPHON | ZMK MEDICAL TECHNOLOGIES, D/B/A EIGEN, CA | $224,926 | ZRG1 |
| 2014 | Novel scFv-Antibody Fusion siRNA Carrier Protein for Macroglobulinemia Treatment1R41CA186101-01 · under PA-13-089 | GARAVITO, R MICHAEL | SIRNAX, INC., MI | $224,921 | ZRG1 |
| 2014 | Targeting DNA damage response pathways for the treatment of advanced lung cancer1R41ES025596-01A1 | FREEMAN, MICHAEL L. | CUMBERLAND PHARMACEUTICALS, INC., TN | $224,910 | ZRG1 |
| 2014 | Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics1R41CA189620-01 | MCINNES, CAMPBELL | PPI PHARMACEUTICALS, LLC, SC | $224,898 | ZRG1 |
| 2014 | Developing a Nrf2 activator for the treatment of COPD1R41HL122004-01A1 | ALLAWAY, GRAHAM P | CUREVEDA, LLC, MD | $224,896 | ZRG1 |
| 2014 | Prevention of erectile dysfunction following prostate cancer radiotherapy1R41CA186431-01 | KAYTOR, MICHAEL DVUJASKOVIC, ZELJKO | HUMANETICS CORPORATION, MN | $224,891 | ZRG1 |
| 2014 | Developing a Nrf2 activator for the treatment of scleroderma1R41AR066418-01 | ALLAWAY, GRAHAM P | CUREVEDA, LLC, MD | $224,858 | ZRG1 |
| 2014 | Field-Side Mobile-Device Oculomotor Function Assessment1R41NS087666-01 | RICHARDS, NATHAN D | BARRON ASSOCIATES, INC., VA | $224,810 | ZRG1 |
| 2014 | EKO Approach To Find Small Molecules That Perturb Protein Protein Interaction1R41GM108153-01A1 | BURGESS, KEVIN | SMALL MOLECULE PPI MIMICS, LLC, TX | $224,800 | ZRG1 |
| 2014 | Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome1R42AA024003-01A1 | ROJAS, MAURICIOTING, ANTHONY | ATHERSYS, INC., OH | $224,721 | ZRG1 |
| 2014 | Using Structuring Interacting RNAs (sxRNAs) as microRNA Inhibitors1R41GM110877-01 | TENENBAUM, SCOTT A | HOCUSLOCUS, INC., NY | $224,609 | ZRG1 |
| 2014 | Targeting of Myc-Max dimerization for the treatment of cancer1R41CA189600-01 | KAUFMANN, GUNNAR JOERG FLORIS | SORRENTO THERAPEUTICS, INC., CA | $224,550 | ZRG1 |
| 2014 | Geriatric Symptom Protocols for Improved Triage in Offices and Assisted Living1R41NR015200-01 | OAKKAR, OAKKAR | KEONA HEALTH, INC., NC | $224,543 | ZRG1 |
| 2014 | Development of fluorescence-based receptor binding assays for the detection1R41ES023724-01A1 | MCCALL, JENNIFER RETTEW | SEATOX RESEARCH, INC., NC | $224,408 | ZRG1 |
| 2014 | Real-time bioimpedance based biopsy device1R41CA192502-01A1 | HALTER, RYAN JOSEPH | RYTEK MEDICAL, INC., NH | $223,942 | ZRG1 |
| 2014 | Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat1R41AG050021-01 | GRANDE, DANIEL A. | TRAVERSE BIOSCIENCES, INC., NY | $223,797 | ZRG1 |
| 2014 | Novel coatings releasing synergistic polyphenols promote vascular healing1R41HL123334-01 | DUGAS, TAMMY R | REQUISITE BIOMEDICAL, LLC, LA | $223,701 | ZRG1 |
| 2014 | Development and in vitro validation of therapy for mucopolysaccharidosis III1R41NS089061-01 | EKINS, SEAN | PHOENIX NEST, INC., NY | $223,102 | ZRG1 |
| 2014 | Feasibility of Non-surgical Implant Adjustment1R41AR067008-01 | FENING, STEPHEN DANIEL | APTO ORTHOPAEDICS CORPORATION, OH | $222,908 | ZRG1 |
| 2014 | Targeting the chondrosarcoma extracellular matrix for drug delivery1R41CA183208-01 · under PA-13-089 | HOHL, RAYMOND J. | TERPENOID THERAPEUTICS, INC., IA | $222,881 | ZRG1 |
| 2014 | MDCT Quantification of hepatic tumor viability for assessment of cancer therapy1R41CA189637-01 | CAI, WENLIWU, YIN | IQ MEDICAL IMAGING, LLC, MA | $222,795 | ZRG1 |
| 2014 | Disposable paper-based electrochemical metal ion sensors for water safety testing1R41ES024626-01 | LAI, REBECCA Y | ZANSORS, LLC, VA | $222,639 | ZRG1 |
| 2014 | Drug Delivery Method for Sudden Sensorineural Hearing Loss1R41DC013534-01A1 | SHAPIRO, BENJAMIN | WEINBERG MEDICAL PHYSICS, LLC, MD | $222,527 | ZRG1 |
| 2014 | Selective activation of the vagus nerve as an improved therapy for heart failure1R41HL121897-01 · under PA-13-089 | DOWDEN, BRETT ROSS | BLACKROCK MICROSYSTEMS, UT | $222,049 | ZRG1 |
| 2014 | Use of EF2K Inhibitors to Reduce Toxicity to Normal Tissues in Chemotherapy1R41CA192929-01 | RYAZANOV, ALEXEY G. | LONGEVICA PHARMACEUTICALS, INC., NJ | $222,039 | ZRG1 |
| 2014 | Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy1R41AR067014-01 | BURKIN, DEAN J. | STRYKAGEN CORPORATION, NV | $219,857 | ZRG1 |
| 2014 | NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics1R41AG048723-01 | JOHNSON, JON W.MYERS, SCOTT JAMES | NEUROP, INC., GA | $219,338 | ZRG1 |
| 2014 | Developing a Novel eHealth Application for Oral Systemic Issues during Pregnancy1R41DE023723-01A1 | CHRISTIANSEN, STEVEN MVAMOS, CHERYL | C/J MEDIA, INC., OR | $219,183 | ZRG1 |
| 2014 | Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal1R41CA189537-01 | DESIR, GARY V. | BESSOR PHARMA, LLC, MA | $219,130 | ZRG1 |
| 2014 | Cblb-based Drugs Against Sepsis and Inflammation1R41HL118896-01A1 · under PA-13-089 | BACHMAIER, KURTGAO, XIAO-PEI | CELL BIOLOGICS, INC., IL | $218,510 | ZRG1 |
| 2014 | Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells1R41CA176962-01A1 · under PA-13-089 | CHERVIN, ADAM | IMMUVEN, INC., IL | $218,309 | ZRG1 |
| 2014 | Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery1R41CA192504-01 | SHEKHAR, RAJ | IGI TECHNOLOGIES, INC., MD | $217,875 | ZRG1 |
| 2014 | Transdermal H2S Sensing Device for Monitoring Peripheral Artery Disease1R41HL121871-01 · under PA-13-089 | KANAGY, NANCY LSHEKARRIZ, REZA | EXHALIX, LLC, NM | $215,724 | ZRG1 |
| 2014 | High Z Oraya Therapy for wet AMD1R41EY024197-01 · under PA-13-089 | CHELL, ERIK WILLIAMMAKRIGIORGOS, G. MIKE | ORAYA THERAPEUTICS, INC, CA | $215,200 | ZRG1 |
| 2014 | Amplification-free megabase target-enrichment for next-generation sequencing1R41HG008117-01 | EASTBURN, DENNIS J | MISSION BIO, INC., CA | $215,000 | ZRG1 |
| 2014 | Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma1R41CA183197-01 · under PA-13-089 | MILLS, KEVIN D | CYTEIR THERAPEUTICS, INC., MA | $213,466 | ZRG1 |
| 2014 | Sympathetic Nerve Activity Recorded From the Skin and Cardiac Arrhythmias1R41HL124741-01 | EVERETT, THOMAS H | ARRHYTHMOTECH, LLC, IN | $212,634 | ZRG1 |
| 2014 | Universal amplifier system for high-fidelity multi-modal biosignal recordings1R41AT008649-01A1 | COMBS, WILLIAM | REFER2INPUT, LLC, IN | $210,581 | ZRG1 |
| 2014 | Hand Rehabilitation using Variable Assistance through Force and EMG Feedback1R41AG049499-01A1 | KNUESEL, ROBERT J | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $209,990 | ZRG1 |
| 2014 | Novel pharmacogenomic approach for identifying T cell epitopes in replacement FVI1R41MD008809-01 · under PA-13-089 | LILLARD, JAMES W | HAPLOMICS, INC., CA | $203,849 | ZRG1 |
| 2014 | A novel therapeutic approach for Acute Lung Injury/ARDS1R41HL124817-01 | ADLER, KENNETH BRUCE | BIOMARCK PHARMACEUTICALS, LTD, NC | $201,503 | ZRG1 |
| 2014 | Multi-functional particles for stem cell isolation and expansion1R41MH106303-01 · under PA-13-089 | HU, WENJING | PROGENITEC, INC., TX | $200,251 | ZRG1 |
| 2014 | New generation of catheters for treatment of atrial fibrillation1R41HL120511-01A1 | SARVAZYAN, NARINE | NOCTURNAL PRODUCT DEVELOPMENT, LLC, NC | $200,001 | ZRG1 |
| 2014 | Combinatorial RXR-based therapeutics for Alzheimer's disease1R41AG048658-01 | GHOSAL, KAUSHIK | REXCEPTOR, INC., OH | $199,122 | ZRG1 |
| 2014 | A Doppler Simulator for Vascular Ultrasound Training1R41EB018124-01A1 | LEOTTA, DANIEL FSHEEHAN, FLORENCE | SHEEHAN MEDICAL, LLC, WA | $197,632 | ZRG1 |
| 2014 | Picture Me Fit: Engaging Youth in Community-Based Prevention1R41NR015736-01A1 · under PA-12-089 | STRACK, ROBERT W. | PREVENTION STRATEGIES, LLC, NC | $197,524 | ZRG1 |
| 2014 | Testing Smad7-based biologics for treating chronic wounds1R41AR067106-01 | WANG, XIAO-JING | TAIGA BIOTECHNOLOGIES, INC., CO | $194,672 | ZRG1 |
| 2014 | The Emotion Builder: An Intervention for Emotional Deficits after Brain Injury1R41HD077967-01A1 | NEUMANN, DAWN MARIE | EMOTED, INC., IN | $194,575 | ZRG1 |
| 2014 | New Functionally-Graded Biohybrid Vascular Graft1R41TR001009-01A1 · under PA-12-089 | VOHRA, YOGESH K. | VIVO BIOSCIENCES, INC., AL | $192,314 | ZRG1 |
| 2014 | Flexible Ion-Mediated Artificial Retina1R41EY023461-01A1 | BIRGE, ROBERT RICHARDS | LAMBDAVISION, INC., CT | $190,499 | ZRG1 |
| 2014 | A novel 3D cell culture human uterine contractility assay for high-throughput scr1R41HD081795-01 | GODIN, BIANAREFUERZO, JERRIE SELGASOUZA, GLAUCO RANNA | NANO3D BIOSCIENCES, INC., TX | $190,468 | ZRG1 |
| 2014 | Harvesting specific plant metabolites from hairy root cultures using magnetized n1R41AT008312-01 | LITTLETON, JOHN M. | NAPROGENIX, INC, KY | $189,844 | ZRG1 |
| 2014 | Modernize animal pharming with emerging gene targeting technologies1R41GM110822-01 | XU, JIE | APPLIED STEMCELL, INC., CA | $186,180 | ZRG1 |
| 2014 | Mitochondrial Uncoupling as a Therapeutic Target in Obesity1R41DK097862-01A1 · under PA-13-089 | SULLIVAN, PATRICK G | NANO-MITE TECHNOLOGIES, LLC, KY | $183,070 | ZRG1 |
| 2014 | Removal of Amyloid-beta Peptides from the Alzheimer's Brain1R41AG046976-01A1 | QIU, WEI QIAO WENDYZHU, HAIHAO | WE BIOSCIENCES, LLC, CT | $172,361 | ZRG1 |
| 2014 | Accurate Prostate Cancer Diagnosis for Active Surveillance Patients Using a Novel1R41CA183315-01 · under PA-13-089 | MONTGOMERY, JEFFREY SCOTT | PRODEVICE MEDICAL SUPPLIES AND EQUIPMENT, MI | $161,003 | ZRG1 |
| 2014 | Ex vivo purging strategy for treatment of multiple myeloma1R41CA179706-01A1 | MCFADDEN, GRANT | DNATRIX, INC., CA | $160,632 | ZRG1 |
| 2014 | Manufacture of Self-Reporting, Drug Loaded Porous Silicon Nanomaterials for Treat1R41EY023482-01 · under PA-12-089 | ANGLIN, EMILY JESSICA | SPINNAKER BIOSCIENCES, INC., CA | $159,384 | ZRG1 |
| 2014 | Novel Pharmacotherapeutic Bioadhesive Patch for Oral Ulcerations1R41DE024343-01 | LIU, XIAOHUA | POST OAK PHARMACEUTICALS, INC., TX | $151,583 | ZRG1 |
| 2014 | Minimal piggyBac vectors for chromatin integration1R41GM109527-01 · under PA-13-089 | SOLODUSHKO, VICTOR | EXSCIEN CORPORATION, AL | $150,576 | ZRG1 |
| 2014 | Development of a Neuroprotective Agent For Cerebral Palsy Prevention1R41HD079201-01A1 | GALINDO, RAFAELMOVSAS, TAMMY Z | ZIETCHICK RESEARCH INSTITUTE, LLC, MI | $150,372 | ZRG1 |
| 2014 | Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes1R41DK096772-01A1 | PADUKONE, NANDAN | JENESIS BIOSCIENCES, LLC, MA | $150,000 | ZRG1 |
| 2014 | Recyclable Magnetic Co/C Hybrid ROMP Reagents, Scavengers and Ligands1R42GM112449-01 | HANSON, PAUL R. | MATERIA, INC., CA | $150,000 | ZRG1 |
| 2014 | Surface-covering gels for broad-spectrum antimicrobial protection following open1R41AR065917-01 · under PA-13-089 | VERNON, BRENT L | SONORAN BIOSCIENCES, INC., AZ | $149,967 | ZRG1 |
| 2014 | Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis1R41AR066438-01 | GILJOHANN, DAVID A. | EXICURE, INC., IL | $149,941 | ZRG1 |
| 2014 | Development and wear testing of bi-material bearing surfaces for hip arthroplasty1R41AG050020-01A1 | VAN CITTERS, DOUGLAS W | CORNERSTONE PARTNERS, LLC, VT | $149,873 | ZRG1 |
| 2014 | Microbial Surrogate Assay for Environmental PAH Exposure1R41ES025528-01 | ADAMI, GUY RICHARD | ARPHION, LTD, IL | $148,530 | ZRG1 |
| 2014 | A daily client check-in system for outpatient substance abuse treatment1R41DA036949-01 · under PA-13-089 | CARSWELL, STEVEN BERNARD | COG ANALYTICS, LLC, MD | $147,735 | ZRG1 |
| 2014 | Development of small near-infrared laser system capable of improving immune respo1R41AI114012-01 | CALLAHAN, JOHN JAMES | SEMINEX CORPORATION, MA | $146,905 | ZRG1 |
| 2014 | Advanced Assessment to Accelerate Diagnostic Skill Acquisition1R41GM108104-01A1 | CIANCIOLO, ANNALAVOIE, NOELLE | PARALLEL CONSULTING, LLC, CA | $144,721 | ZRG1 |
| 2014 | Science Take-Out Kits for Environmental Health Education1R41ES023706-01 · under PA-13-089 | HOLT, SUSANMARKOWITZ, DINA GROSSMAN | SCIENCE TAKE-OUT, LLC, NY | $143,497 | ZRG1 |
| 2014 | A Wireless Device to Monitor and Track Fluid Consumption in At-Risk Older Adults1R41NR015191-01 | DIMARIA-GHALILI, ROSE ANNPOURREZAEI, AMIRPOURREZAEI, KAMBIZ | SMART ACTIVITY OF DAILY LIVING, LLC, PA | $142,066 | ZRG1 |
| 2014 | Ovarian cancer using novel nanoparticle formulations1R41CA180773-01A1 | CHIRIVA-INTERNATI, MAURIZIOD'SOUZA, MARTIN J. | KIROMIC, INC., TX | $121,003 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.